胸腔内抗肿瘤药物治疗非小细胞肺癌伴恶性胸腔积液的研究进展
Progress in the Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion with Intrathoracic Antitumor Agents
摘要: 非小细胞肺癌伴恶性胸腔积液是一种严重的疾病，可导致呼吸困难、疼痛、恶病质和体力活动减少，非小细胞肺癌合并恶性胸腔积液的发生往往提示预后不佳。尽管目前有许多治疗方法可用于治疗恶性胸腔积液，但没有一种方法是完全有效的，大多数只能缓解患者的症状。胸腔内抗肿瘤药物治疗不仅能减少胸腔积液的渗出，还能够协同全身抗肿瘤作用。因此，研究胸腔内抗肿瘤药物治疗是对治疗非小细胞肺癌伴恶性胸腔积液患者的合理策略。本文通过系统地回顾和分析国内外文献，总结了目前胸腔内抗肿瘤药物治疗非小细胞肺癌伴恶性胸腔积液的研究进展。旨在为临床医生提供实用的治疗手段，进一步提高非小细胞肺癌伴恶性胸腔积液患者的生存率。
Abstract: Non-small cell lung cancer with malignant pleural effusion is a serious disease that can lead to dyspnea, pain, cachexia and reduced physical activity. The occurrence of malignant pleural effusion with non-small cell lung cancer often indicates a poor prognosis. Although many treatments are currently available to treat malignant pleural effusion, none are completely effective and most only relieve the patient’s symptoms. Intrathoracic antitumor drug therapy can not only reduce the effusion of pleural effusion, but also coordinate the anti-tumor effect of the whole body. Therefore, the study of intrathoracic antitumor therapy is a reasonable strategy for the treatment of patients with non-small cell lung cancer with malignant pleural effusion. Based on the systematic review and analysis of domestic and foreign literature, this paper summarizes the current research progress of intrathoracic antitumor drugs in the treatment of non-small cell lung cancer with malignant pleural effusion. The aim is to provide a practical treatment for clinicians and further improve the survival rate of patients with non-small cell lung cancer with malignant pleural effusion.
文章引用：方思雨, 李长毅. 胸腔内抗肿瘤药物治疗非小细胞肺癌伴恶性胸腔积液的研究进展[J]. 临床医学进展, 2024, 14(11): 1456-1463. https://doi.org/10.12677/acm.2024.14113032

参考文献

[1] 秦叔逵, 杨柳青, 梁军, 等. 腔内应用重组人血管内皮抑制素和/或顺铂治疗恶性胸腹腔积液的前瞻性、 随机对照、全国多中心III期临床研究[J]. 临床肿瘤学杂志, 2017, 22(3): 193-202.
[2] Porcel, J., Rahman, N. and McCracken, D. (2018) Malignant Pleural Effusions: Management Options. Seminars in Respiratory and Critical Care Medicine, 39, 704-712. [Google Scholar] [CrossRef] [PubMed]
[3] Morgensztern, D., Waqar, S., Subramanian, J., Trinkaus, K. and Govindan, R. (2012) Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 7, 1485-1489. [Google Scholar] [CrossRef] [PubMed]
[4] Chen, R.L., Zhang, C.C., Wu, H., et al. (2016) Clinical Effect of Pleural Perfusion of Human Recombinant Endostatin Injection Combined with Cisplatin Injection on Advanced Non-Small Cell Lung Cancer Complicated with Malignant Pleural Effusion. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 24, 118-120.
[5] 侯俊杰, 方艳秋, 杨影, 等. 中国肺癌相关性恶性胸腔积液治疗进展[J]. 中国免疫学杂志, 2022, 38(2): 243-248.
[6] Mierzejewski, M., Korczynski, P., Krenke, R. and Janssen, J.P. (2019) Chemical Pleurodesis – A Review of Mechanisms Involved in Pleural Space Obliteration. Respiratory Research, 20, Article No. 247. [Google Scholar] [CrossRef] [PubMed]
[7] Chu, H., Du, F., Gong, Z., et al. (2017) Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin through Intrapleural and Intraperitoneal in Fusion. Anticancer Research, 37, 4587-4591.
[8] Wu, K., Lu, H.Y. and Duan, D.J. (2012) Clinical Observation of Intrapleural Injection of Endostar Combined with Cisplatin (DDP) in Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion. Clinical Pulmonary Medicine, 17, 107-108.
[9] Zhong, L., Xu, H., Zhao, Z., Zhang, G. and Lin, F. (2018) Comparison of Efficacy and Toxicity between Nedaplatin and Cisplatin in Treating Malignant Pleural Effusion. OncoTargets and Therapy, 11, 5509-5512. [Google Scholar] [CrossRef] [PubMed]
[10] 李洲强. 中药注射液联合顺铂治疗肺癌恶性胸腔积液的网状meta分析和网络药理学研究[D]: [硕士学位论文]. 南宁: 广西中医药大学, 2022.
[11] 吴成焱, 李劲, 吴幸谕, 等. 复方苦参注射液联合顺铂治疗恶性胸腔积液的临床研究[J]. 辽宁中医杂志, 2019, 46(1): 85-87.
[12] 冯活林, 倪雪莉, 黄锡英, 等. 复方苦参注射液联合顺铂胸腔灌注治疗老年恶性胸腔积液的临床研究[J]. 中医临床研究, 2019, 11(2): 141-142.
[13] Zhong, L., Xu, H., Zhao, Z., Zhang, G. and Lin, F. (2018) Comparison of Efficacy and Toxicity between Nedaplatin and Cisplatin in Treating Malignant Pleural Effusion. OncoTargets and Therapy, 11, 5509-5512. [Google Scholar] [CrossRef] [PubMed]
[14] Hirose, T., Sugiyama, T., Kusumoto, S., et al. (2009) Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer. Anticancer Research, 29, 1733-1738.
[15] 黄韵映, 汪宝贞. 奈达铂腔内灌注治疗非小细胞肺癌恶性胸腔积液效果分析[J]. 中外医学研究, 2018, 16(10): 18-19.
[16] Choi, M.G., Park, S., Oh, D.K., Kim, H.R., Lee, G.D., Lee, J.C., et al. (2019) Effect of Medical Thoracoscopy-Guided Intrapleural Docetaxel Therapy to Manage Malignant Pleural Effusion in Patients with Non-Small Cell Lung Cancer: A Pilot Study. Thoracic Cancer, 10, 1885-1892. [Google Scholar] [CrossRef] [PubMed]
[17] 高伟艳, 赵玲, 顾爱丽, 等. 洛铂胸腔灌注治疗晚期非小细胞肺癌恶性胸腔积液临床观察[J]. 肿瘤基础与临床, 2019, 32(1): 28-30.
[18] Donnenberg, A.D., Luketich, J.D., Dhupar, R. and Donnenberg, V.S. (2019) Treatment of Malignant Pleural Effusions: The Case for Localized Immunotherapy. Journal for Immunotherapy of Cancer, 7, Article 110. [Google Scholar] [CrossRef] [PubMed]
[19] Yanagawa, H., Haku, T., Hiramatsu, K., Nokihara, H., Takeuchi, E., Yano, S., et al. (1997) Intrapleural Instillation of Interferon in Patients with Malignant Pleurisy Due to Lung Cancer. Cancer Immunology, Immunotherapy, 45, 93-99. [Google Scholar] [CrossRef] [PubMed]
[20] Sartori, S., Tassinari, D., Ceccotti, P., Tombesi, P., Nielsen, I., Trevisani, L., et al. (2004) Prospective Randomized Trial of Intrapleural Bleomycin versus Interferon Alfa-2b via Ultrasound-Guided Small-Bore Chest Tube in the Palliative Treatment of Malignant Pleural Effusions. Journal of Clinical Oncology, 22, 1228-1233. [Google Scholar] [CrossRef] [PubMed]
[21] Goey, S., Eggermont, A., Punt, C., Slingerland, R., Gratama, J., Oosterom, R., et al. (1995) Intrapleural Administration of Interleukin 2 in Pleural Mesothelioma: A Phase I-II Study. British Journal of Cancer, 72, 1283-1288. [Google Scholar] [CrossRef] [PubMed]
[22] 邹媚, 李燕, 周自华. 香菇多糖联合白介素-2序贯洛铂胸腔灌注治疗非小细胞肺癌合并恶性胸腔积液的疗效观察[J]. 中国处方药, 2021, 19(9): 121-123.
[23] 郭丽. 非小细胞肺癌恶性胸腔积液胸腔注药疗效观察[J]. 家庭医药, 2018(5): 171.
[24] Qi, N., Li, F., Li, X., Kang, H., Zhao, H. and Du, N. (2016) Combination Use of Paclitaxel and Avastin Enhances Treatment Effect for the NSCLC Patients with Malignant Pleural Effusion. Medicine, 95, e5392. [Google Scholar] [CrossRef] [PubMed]
[25] 崔淼, 刘双. 腔内注射对恶性胸腔积液治疗效果的研究进展[J]. 中国继续医学教育, 2021, 13(11): 195-198.
[26] Jie, W.X., Miao, K., Luo, Y., et al. (2018) Randomized Controlled Trial of Endostar Combined with Cisplatin/Pemetrexed Chemotherapy for Elderly Patients with Advanced Malignant Pleural Effusion of Lung Adenocarcinoma. Journal of Balkan Union of Oncology, 23, 92-97.
[27] 徐敏, 陈永发, 胡建新. 恩度联合顺铂胸腔内灌注治疗非小细胞肺癌大量恶性胸腔积液的临床观察[J]. 广东医科大学学报, 2020, 38(2): 178-180.
[28] 陈瑞琳, 张程程, 吴桦, 等. 重组人血管内皮抑制素注射液联合顺铂注射液胸腔灌注治疗晚期非小细胞肺癌恶性胸腔积液的临床疗效观察[J]. 实用心脑肺血管病杂志, 2016, 24(5): 118-120.
[29] 李化龙, 蔡树华, 赵改梅, 等. 重组人血管内皮抑制素注射液联合洛铂治疗恶性胸腔积液临床效果观察[J]. 中国医学前沿杂志(电子版), 2016, 8(12): 42-45.
[30] 卢筠, 谢强, 陈群, 等. 重组人血管内皮抑素联合顺铂胸腔内注射治疗肺腺癌恶性胸腔积液的临床研究[J]. 临床肺科杂志, 2016, 21(9): 1664-1666+1667.
[31] 郑伟, 康静波, 温居一, 等. 重组人血管内皮抑制素联合顺铂对恶性胸腔积液患者VEGF、EGFR及肿瘤标志物的影响[J]. 实用临床医药杂志, 2016, 20(23): 32-35.
[32] 徐转转, 涂超超, 龚章沁, 等. 重组人血管内皮抑制素不同给药方式治疗非小细胞肺癌恶性胸腔积液的有效性和安全性的网状Meta分析[J]. 中国药师, 2024, 27(4): 697-710.
[33] Chen, L., Zhu, X., Li, D. and Cai, X. (2020) Effect of Thoracic Hyperthermic Perfusion with Recombinant Human Endostatin plus Nedaplatin in Treating Pleural Effusion in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Balkan Union of Oncology, 25, 2643-2649.
[34] Du, N., Li, X., Li, F., Zhao, H., Fan, Z., Ma, J., et al. (2013) Intrapleural Combination Therapy with Bevacizumab and Cisplatin for Non-Small Cell Lung Cancer-Mediated Malignant Pleural Effusion. Oncology Reports, 29, 2332-2340. [Google Scholar] [CrossRef] [PubMed]
[35] Nie, K., Zhang, Z., You, Y., Zhuang, X., Zhang, C. and Ji, Y. (2019) A Randomized Clinical Study to Compare Intrapleural Infusion with Intravenous Infusion of Bevacizumab in the Management of Malignant Pleural Effusion in Patients with Non-Small-Cell Lung Cancer. Thoracic Cancer, 11, 8-14. [Google Scholar] [CrossRef] [PubMed]
[36] Di, W., Yue, C., Ziran, Z., Jie, Z., Jun, N., Ling, D., et al. (2022) A Phase II Study of Bevacizumab in Non-Squamous, Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusion. Future Oncology, 18, 669-677. [Google Scholar] [CrossRef] [PubMed]
[37] Zhou, Z., Li, H., Hu, D. and Xie, L. (2021) Clinical Efficacy of Bevacizumab Combined with Cisplatin in the Treatment of Malignant Pleural Effusion and Ascites Caused by Lung Cancer: A Randomized Trial. Annals of Palliative Medicine, 10, 10575-10583. [Google Scholar] [CrossRef] [PubMed]
[38] Jayson, G.C., Kerbel, R., Ellis, L.M. and Harris, A.L. (2016) Antiangiogenic Therapy in Oncology: Current Status and Future Directions. The Lancet, 388, 518-529. [Google Scholar] [CrossRef] [PubMed]
[39] Tamiya, M., Tamiya, A., Suzuki, H., Taniguchi, Y., Katayama, K., Minomo, S., et al. (2021) Phase 2 Study of Bevacizumab Plus Carboplatin/Nab-Paclitaxel Followed by Bevacizumab Plus Nab-Paclitaxel for Non-Squamous Non-Small Cell Lung Cancer with Malignant Pleural Effusion. Investigational New Drugs, 39, 1106-1112. [Google Scholar] [CrossRef] [PubMed]
[40] Murthy, P., Ekeke, C.N., Russell, K.L., Butler, S.C., Wang, Y., Luketich, J.D., et al. (2019) Making Cold Malignant Pleural Effusions Hot: Driving Novel Immunotherapies. OncoImmunology, 8, e1554969. [Google Scholar] [CrossRef] [PubMed]
[41] Lin, H., Tong, Z., Xu, Q., Wu, X., Wang, X., Jin, X., et al. (2014) Interplay of Th1 and Th17 Cells in Murine Models of Malignant Pleural Effusion. American Journal of Respiratory and Critical Care Medicine, 189, 697-706. [Google Scholar] [CrossRef] [PubMed]
[42] Qin, X., Shi, H., Deng, J., Liang, Q., Jiang, J. and Ye, Z. (2009) CCL22 Recruits Cd4-Positive Cd25-Positive Regulatory T Cells into Malignant Pleural Effusion. Clinical Cancer Research, 15, 2231-2237. [Google Scholar] [CrossRef] [PubMed]
[43] Stathopoulos, G.T., Psallidas, I., Moustaki, A., Moschos, C., Kollintza, A., Karabela, S., et al. (2008) A Central Role for Tumor-Derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion. Journal of the National Cancer Institute, 100, 1464-1476. [Google Scholar] [CrossRef] [PubMed]
[44] Pedoeem, A., Azoulay-Alfaguter, I., Strazza, M., Silverman, G.J. and Mor, A. (2014) Programmed Death-1 Pathway in Cancer and Autoimmunity. Clinical Immunology, 153, 145-152. [Google Scholar] [CrossRef] [PubMed]
[45] Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., et al. (2020) Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (Oncology Program by Innovent Anti-pd-1-11). Journal of Thoracic Oncology, 15, 1636-1646. [Google Scholar] [CrossRef] [PubMed]
[46] Guo, X.L. and Li, J. (2017) Compound Kushen Injection Combined with Sorafenib in the Treatment of Advanced Primary Liver Cancer. Modern Medicine and Clinical, 32, 258-262.
[47] 李斌. 复方苦参注射液联合化疗治疗非小细胞肺癌临床研究[J]. 辽宁中医杂志, 2022, 49(4): 138-139.
[48] 孙婧, 许鹏, 鱼麦侠, 等. 复方苦参注射液联合胸腔灌注治疗恶性胸腔积液的临床效果[J]. 临床医学研究与实践, 2019, 4(13): 48-49.
[49] 刘学, 刘丹丹. 复方苦参注射液联合顺铂治疗恶性胸腔积液疗效及不良反应观察[J]. 临床医药文献电子杂志, 2020, 7(14): 135-140.
[50] 王云, 范韶伟, 罗强, 等. 胸膜腔置管引流并灌注复方苦参注射液联合顺铂治疗肺癌恶性胸腔积液的近期疗效[J]. 世界最新医学信息文摘, 2019, 19(2): 123+128.
[51] 冯福凯, 史学军. 复方苦参注射液联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J]. 现代药物与临床, 2023, 38(7): 1717-1721.
[52] 李建亮, 张秋月, 刘英超. 榄香烯联合恩度及顺铂治疗非小细胞肺癌恶性胸腔积液的疗效观察[J]. 山东第一医科大学(山东省医学科学院)学报, 2024, 45(5): 278-282.
[53] 高树会, 张桂彬, 闫莉, 等. 榄香烯联合洛铂对晚期非小细胞肺癌合并恶性胸腔积液的疗效观察[J]. 国际检验医学杂志, 2023, 44(15): 1868-1872.
[54] 董婷, 崔丽花, 毛露凤, 等. 百合固金汤加减联合顺铂胸腔内注射治疗非小细胞肺癌合并恶性胸腔积液临床研究[J]. 新中医, 2020, 52(18): 40-43.
[55] 张恒丽, 张正伟. 康莱特联合胸腔低渗保留灌注紫杉醇加洛铂治疗非小细胞肺癌并发恶性胸腔积液的临床观察[J]. 临床内科杂志, 2022, 39(7): 472-474.
[56] 莫安薇, 麦泽锋, 王燕艳, 等. 康莱特注射液联合洛铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J]. 现代药物与临床, 2019, 34(4): 1080-1083.
[57] 侯善群. 周剂量顺铂联合胸腺肽胸腔灌注治疗非小细胞肺癌并恶性胸腔积液的近期疗效和安全性[J]. 临床合理用药杂志, 2021, 14(1): 69-70.
[58] 施晓倩. 三氧化二砷胸腔内注射治疗非小细胞肺癌恶性胸腔积液的临床与机制研究[D]: [硕士学位论文]. 重庆: 中国人民解放军海军军医大学, 2019.
[59] 李志国. 培美曲塞二钠化疗联合斑蝥酸钠维生素B6、白介素-2、顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2018.
[60] 胡二斌. 洛铂联合斑蝥酸钠维生素B6注射液胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床研究[Z]. 廊坊: 廊坊市第四人民医院, 2020-06-27.
[61] Dong, X., Huang, Y., Yi, T., Hu, C., Gao, Q., Chen, Y., et al. (2022) Intrapleural Infusion of Tumor Cell-Derived Microparticles Packaging Methotrexate or Saline Combined with Pemetrexed-Cisplatin Chemotherapy for the Treatment of Malignant Pleural Effusion in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Double-Blind, Randomized, Placebo-Controlled Study. Frontiers in Immunology, 13, Article 1002938. [Google Scholar] [CrossRef] [PubMed]

为你推荐